Ernexa Therapeutics Inc. reported a net loss of approximately $14.1 million for the fiscal year ending December 31, 2025, a significant improvement compared to a net loss of $44.5 million in the previous year. The company did not generate any revenue during 2025, a decrease from $582,000 in 2024, primarily due to the assignment of a customer contract to Factor Limited, which resulted in no further revenue-generating contracts. Total operating expenses decreased to $9.3 million from $16.2 million in 2024, driven by reductions in general and administrative expenses, including a notable decrease in occupancy costs following the termination of a sublease.
In terms of strategic developments, Ernexa entered into a significant Exclusive License and Collaboration Agreement with Factor Limited in September 2024, which allows the company to develop certain licensed technologies in cancer and autoimmune disorders. This agreement is expected to facilitate the advancement of Ernexa's lead product candidate, ERNA-101, which is currently in preclinical development for platinum-resistant ovarian cancer. The company had a successful pre-Investigational New Drug (IND) meeting with the FDA in late 2025 and plans to submit an IND application in 2026, with a Phase I clinical trial anticipated to begin in the second half of 2026.
Operationally, Ernexa's employee headcount remained low, with five full-time employees and two part-time employees as of March 12, 2026. The company is actively seeking strategic partnerships to co-develop or out-license therapeutic assets and is applying for research grants to support its development efforts. The company has also been accepted into the Japan External Trade Organization acceleration program, which will provide guidance on entering the Japanese market.
Financially, Ernexa's cash position was approximately $1.9 million as of December 31, 2025, with an accumulated deficit of $245.6 million. The company completed a public offering in February 2026, raising approximately $9.5 million in net proceeds, which is expected to support its development programs and working capital needs. However, the company has indicated that it will require substantial additional capital to fund its operations and execute its business strategy, raising concerns about its ability to continue as a going concern if it cannot secure necessary financing.
Looking ahead, Ernexa's management remains cautious, emphasizing the need for additional capital to sustain operations. The company is focused on advancing its product candidates through clinical trials while navigating the complexities of regulatory approvals and market competition. The ongoing development of its synthetic allogeneic iMSC therapies positions Ernexa within a competitive landscape, where it faces challenges from established pharmaceutical companies and emerging technologies in the biotechnology sector.
About Ernexa Therapeutics Inc.
Eterna Therapeutics Inc. is a preclinical-stage biotech company developing allogeneic mesenchymal stem cell (iMSC) therapies for cancer and autoimmune diseases. Its core focus is on off-the-shelf cellular treatments leveraging iPSC-derived stem cells to target solid tumors and inflammation. The company emphasizes innovative gene editing, nucleic acid technologies, and strategic partnerships to advance its pipeline and intellectual property portfolio.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.